210 related articles for article (PubMed ID: 15735228)
1. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences.
Miura Y; Yamamoto N; Tsunekawa S; Taguchi S; Eguchi Y; Ozaki N; Oiso Y
Diabetes Care; 2005 Mar; 28(3):757-8. PubMed ID: 15735228
[No Abstract] [Full Text] [Related]
2. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy.
Galle J; Schwedhelm E; Pinnetti S; Böger RH; Wanner C;
Nephrol Dial Transplant; 2008 Oct; 23(10):3174-83. PubMed ID: 18450829
[TBL] [Abstract][Full Text] [Related]
3. Comparison of telmisartan vs. valsartan in the treatment of mild to moderate hypertension using ambulatory blood pressure monitoring.
Bakris G
J Clin Hypertens (Greenwich); 2002; 4(4 Suppl 1):26-31. PubMed ID: 12147926
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and meta-analysis of telmisartan versus valsartan in the management of essential hypertension.
Zheng Z; Lin S; Shi H
J Clin Hypertens (Greenwich); 2010 Jun; 12(6):414-21. PubMed ID: 20591086
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the effects of three angiotensin II receptor type 1 blockers on metabolic parameters in hypertensive patients with type 2 diabetes mellitus.
Ozaki N; Nomura Y; Sobajima H; Kondo K; Oiso Y
Eur J Intern Med; 2010 Jun; 21(3):236-9. PubMed ID: 20493430
[TBL] [Abstract][Full Text] [Related]
6. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study.
Sharma AM; Davidson J; Koval S; Lacourcière Y
Cardiovasc Diabetol; 2007 Oct; 6():28. PubMed ID: 17910747
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of telmisartan and valsartan as add-on agents for hypertensive patients with morning blood pressure insufficiently controlled by amlodipine monotherapy.
Yoshida H; Akasaka H; Saitoh S; Shimamoto K; Miura T;
Hypertens Res; 2014 Mar; 37(3):225-31. PubMed ID: 24108237
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
[TBL] [Abstract][Full Text] [Related]
9. Beneficial cardiometabolic actions of telmisartan plus amlodipine therapy in elderly patients with poorly controlled hypertension.
Bekki H; Yamamoto K; Sone M; Homma T; Nakata M; Nohara M; Fukami K; Okuda S; Yamagishi S
Clin Cardiol; 2011 Apr; 34(4):261-5. PubMed ID: 21432858
[TBL] [Abstract][Full Text] [Related]
10. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
11. Comparative effects of telmisartan and valsartan on insulin resistance in hypertensive patients with metabolic syndrome.
Ichikawa Y
Intern Med; 2007; 46(17):1331-6. PubMed ID: 17827829
[TBL] [Abstract][Full Text] [Related]
12. Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study.
Nishida Y; Takahashi Y; Susa N; Kanou N; Nakayama T; Asai S
Cardiovasc Diabetol; 2013 Nov; 12():159. PubMed ID: 24180232
[TBL] [Abstract][Full Text] [Related]
13. A prospective, randomized, open-label trial comparing telmisartan 80 mg with valsartan 80 mg in patients with mild to moderate hypertension using ambulatory blood pressure monitoring.
Littlejohn T; Mroczek W; Marbury T; VanderMaelen CP; Dubiel RF
Can J Cardiol; 2000 Sep; 16(9):1123-32. PubMed ID: 11021956
[TBL] [Abstract][Full Text] [Related]
14. Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension.
White WB; Lacourciere Y
J Hypertens; 2004 Oct; 22(10):2035-6; author reply 2036-8. PubMed ID: 15361777
[No Abstract] [Full Text] [Related]
15. Sustained antihypertensive activity of telmisartan compared with valsartan.
Lacourcière Y; Krzesinski JM; White WB; Davidai G; Schumacher H
Blood Press Monit; 2004 Aug; 9(4):203-10. PubMed ID: 15311147
[TBL] [Abstract][Full Text] [Related]
16. Olmesartan reduced microalbuminuria in Japanese subjects with type 2 diabetes.
Ikeda H; Hamamoto Y; Honjo S; Nabe K; Wada Y; Koshiyama H
Diabetes Res Clin Pract; 2009 Jan; 83(1):117-8. PubMed ID: 19062123
[TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of randomized trials of telmisartan vs. valsartan therapy for blood pressure reduction.
Takagi H; Niwa M; Mizuno Y; Goto SN; Umemoto T;
Hypertens Res; 2013 Jul; 36(7):627-33. PubMed ID: 23344134
[TBL] [Abstract][Full Text] [Related]
18. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
Yoneda T; Takeda Y; Usukura M; Oda N; Takata H; Yamamoto Y; Karashima S; Yamagishi M
Am J Hypertens; 2007 Dec; 20(12):1329-33. PubMed ID: 18047925
[TBL] [Abstract][Full Text] [Related]
19. Effect of switching from telmisartan, valsartan, olmesartan, or losartan to candesartan on morning hypertension.
Hasegawa H; Takano H; Kameda Y; Kubota A; Kobayashi Y; Komuro I
Clin Exp Hypertens; 2012; 34(2):86-91. PubMed ID: 22251314
[TBL] [Abstract][Full Text] [Related]
20. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis.
Georgescu EF; Ionescu R; Niculescu M; Mogoanta L; Vancica L
World J Gastroenterol; 2009 Feb; 15(8):942-54. PubMed ID: 19248193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
